Some experts have expressed some skepticism about President Donald Trump’s administration’s plans to reduce drug prices, Fierce Healthcare reports.
The concerns were spurred by the White House Council of Economic Adviser’s 30-page white paper released Feb. 9, which outlines a number of policy changes aimed at cutting drug prices and incentives for pharma to reduce the costs associated with maintaining health.
Trump during his State of the Union address said drug pricing reform was one of his administration’s major goals for 2018.
“I have directed my administration to make fixing the injustice of high drug prices one of my top priorities this year,” he said. “And prices will come down substantially – watch.”
To read more on Fierce Healthcare about the concerns raised by some experts, click here.
